RS51698B - Pyrrolopyrimidines as Protein Kinase Inhibitors - Google Patents
Pyrrolopyrimidines as Protein Kinase InhibitorsInfo
- Publication number
- RS51698B RS51698B YU99203A YUP99203A RS51698B RS 51698 B RS51698 B RS 51698B YU 99203 A YU99203 A YU 99203A YU P99203 A YUP99203 A YU P99203A RS 51698 B RS51698 B RS 51698B
- Authority
- RS
- Serbia
- Prior art keywords
- ny1y2
- ny3y4
- heteroaryl
- aryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MEP-193/08A MEP19308A (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as protein kinase inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0115393.1A GB0115393D0 (en) | 2001-06-23 | 2001-06-23 | Chemical compounds |
US30167801P | 2001-06-28 | 2001-06-28 | |
PCT/GB2002/002835 WO2003000695A1 (fr) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
RS99203A RS99203A (en) | 2006-12-15 |
RS51698B true RS51698B (en) | 2011-10-31 |
Family
ID=9917225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU99203A RS51698B (en) | 2001-06-23 | 2002-06-21 | Pyrrolopyrimidines as Protein Kinase Inhibitors |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1404676A1 (fr) |
JP (1) | JP4344607B2 (fr) |
CN (1) | CN1294135C (fr) |
AU (1) | AU2002314325B8 (fr) |
BR (1) | BR0210652A (fr) |
CA (1) | CA2451932C (fr) |
CZ (1) | CZ20033443A3 (fr) |
EA (1) | EA007415B1 (fr) |
EC (1) | ECSP034922A (fr) |
EE (1) | EE05432B1 (fr) |
GB (1) | GB0115393D0 (fr) |
HU (1) | HUP0400300A3 (fr) |
ME (1) | MEP19308A (fr) |
NZ (1) | NZ529766A (fr) |
OA (1) | OA12632A (fr) |
PL (1) | PL374096A1 (fr) |
RS (1) | RS51698B (fr) |
SK (1) | SK15882003A3 (fr) |
TN (1) | TNSN03144A1 (fr) |
TR (1) | TR200302242T2 (fr) |
UA (1) | UA76760C2 (fr) |
WO (1) | WO2003000695A1 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
MXPA06005578A (es) | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Compuestos de pirrolopirimidina utiles en el tratamiento del cancer. |
JP2007512316A (ja) * | 2003-11-25 | 2007-05-17 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症の治療方法 |
WO2005105788A1 (fr) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Derives d'indole et leur utilisation en tant qu'inhibiteurs de kinases |
FR2876103B1 (fr) * | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
JP2008543855A (ja) | 2005-06-13 | 2008-12-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 変形性骨疾患を処置するための方法および組成物 |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
DK2348023T5 (da) | 2005-12-13 | 2017-05-15 | Incyte Holdings Corp | Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
RS53245B2 (sr) | 2007-06-13 | 2022-10-31 | Incyte Holdings Corp | Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila |
EA201070841A1 (ru) | 2008-01-11 | 2011-02-28 | Натко Фарма Лимитед | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
CA2727032C (fr) | 2008-06-10 | 2018-08-14 | Abbott Laboratories | Composes tricycliques |
EP2432472B1 (fr) | 2009-05-22 | 2019-10-02 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- ou heptane-nitrile en tant qu'inhibiteurs de jak |
AU2010249380B2 (en) | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
WO2011018894A1 (fr) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011029043A1 (fr) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Inhibiteurs hétéroaryles de btk |
RU2570416C9 (ru) | 2009-12-01 | 2019-11-25 | Эббви Инк. | Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
MY178634A (en) | 2010-05-21 | 2020-10-19 | Incyte Corp | Topical formulation for a jak inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
JP5917545B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体 |
CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
CN102093364B (zh) | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
EP2838898B1 (fr) | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Composés hétéro-bicycliques substitués, compositions et leurs applications médicinales |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
PL2877467T3 (pl) | 2012-07-26 | 2017-08-31 | Glaxo Group Limited | 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4 |
EP2892534B8 (fr) | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Composés et procédés pour la modulation des kinases, et leurs indications |
WO2014078486A1 (fr) | 2012-11-15 | 2014-05-22 | Incyte Corporation | Formes galéniques à libération prolongée du ruxolitinib |
KR102366356B1 (ko) | 2013-03-06 | 2022-02-23 | 인사이트 홀딩스 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간생성물 |
MX2015012386A (es) | 2013-03-13 | 2016-02-03 | Abbvie Inc | Inhibidores de la cinasa cdk9. |
CN105189481A (zh) | 2013-03-13 | 2015-12-23 | 艾伯维公司 | 吡啶cdk9激酶抑制剂 |
MX2015012153A (es) | 2013-03-14 | 2015-12-01 | Abbvie Inc | Inhibidores de la quinasa pirrolopirimidina cdk9. |
WO2014139328A1 (fr) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Inhibiteurs de pyrrolo[2,3-b]pyridine cdk9 kinase |
BR112015023187A2 (pt) | 2013-03-14 | 2017-07-18 | Abbvie Inc | inibidores de pirrolo[2,3 - b] piridina cdk9 kinase |
PE20220579A1 (es) | 2013-08-07 | 2022-04-20 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 |
CN104804001B9 (zh) * | 2014-01-24 | 2022-02-08 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
WO2015184305A1 (fr) | 2014-05-30 | 2015-12-03 | Incyte Corporation | Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1 |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
BR112018007677A2 (pt) | 2015-10-16 | 2018-11-06 | Abbvie Inc. | processos para a preparação de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida e suas formas em estado sólido |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
AU2018230500B2 (en) | 2017-03-09 | 2024-03-07 | Abbvie Inc. | Methods of treating Crohn's disease and ulcerative colitis |
WO2019113487A1 (fr) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs |
EP4086245A1 (fr) | 2018-01-30 | 2022-11-09 | Incyte Corporation | Procédés pour fabriquer composés intermediaires pour la synthèse d'un inhibiteur de jak |
SG11202009441PA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
AU2019353144B2 (en) | 2018-10-05 | 2023-11-16 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with APJ receptor activity |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2177925T3 (es) * | 1996-01-23 | 2002-12-16 | Novartis Ag | Pirrolopirimidinas y procedimientos para su preparacion. |
JP2000505109A (ja) * | 1996-11-27 | 2000-04-25 | ファイザー・インク | 縮合二環式ピリミジン誘導体 |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
IL139586A0 (en) * | 1998-06-19 | 2002-02-10 | Pfizer Prod Inc | PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS |
NZ510587A (en) * | 1998-09-18 | 2003-11-28 | Abbott Gmbh & Co | 4-aminopyrrolopyrimidines as kinase inhibitors |
DZ3248A1 (fr) * | 1999-12-10 | 2001-06-14 | Pfizer Prod Inc | Composés à base de pyrrolo[2,3-d]pyrimidine |
-
2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
-
2002
- 2002-06-21 PL PL02374096A patent/PL374096A1/xx not_active Application Discontinuation
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/ja not_active Expired - Fee Related
- 2002-06-21 CA CA002451932A patent/CA2451932C/fr not_active Expired - Fee Related
- 2002-06-21 EP EP02740895A patent/EP1404676A1/fr not_active Withdrawn
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/pt not_active Application Discontinuation
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/xx unknown
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 CN CNB028119320A patent/CN1294135C/zh not_active Expired - Fee Related
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/fr active Application Filing
- 2002-06-21 EA EA200400073A patent/EA007415B1/ru not_active IP Right Cessation
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/xx unknown
- 2002-06-21 EE EEP200400003A patent/EE05432B1/xx not_active IP Right Cessation
- 2002-06-21 RS YU99203A patent/RS51698B/en unknown
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/sk not_active Application Discontinuation
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/cs unknown
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/hu unknown
- 2002-06-21 UA UA2004010502A patent/UA76760C2/uk unknown
-
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP034922A (es) | 2004-04-28 |
CA2451932C (fr) | 2009-12-29 |
CA2451932A1 (fr) | 2003-01-03 |
JP2005508300A (ja) | 2005-03-31 |
CN1518552A (zh) | 2004-08-04 |
TNSN03144A1 (en) | 2005-12-23 |
WO2003000695A1 (fr) | 2003-01-03 |
MEP19308A (en) | 2010-06-10 |
RS99203A (en) | 2006-12-15 |
CZ20033443A3 (en) | 2004-03-17 |
SK15882003A3 (sk) | 2004-07-07 |
EP1404676A1 (fr) | 2004-04-07 |
PL374096A1 (en) | 2005-09-19 |
AU2002314325B8 (en) | 2009-01-29 |
EE200400003A (et) | 2004-02-16 |
BR0210652A (pt) | 2004-08-10 |
CN1294135C (zh) | 2007-01-10 |
WO2003000695A8 (fr) | 2004-03-11 |
GB0115393D0 (en) | 2001-08-15 |
HUP0400300A3 (en) | 2010-12-28 |
EE05432B1 (et) | 2011-06-15 |
AU2002314325B2 (en) | 2009-01-08 |
EA200400073A1 (ru) | 2004-08-26 |
UA76760C2 (uk) | 2006-09-15 |
HUP0400300A2 (en) | 2007-08-28 |
OA12632A (en) | 2006-06-14 |
EA007415B1 (ru) | 2006-10-27 |
TR200302242T2 (tr) | 2004-12-21 |
NZ529766A (en) | 2008-11-28 |
JP4344607B2 (ja) | 2009-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS51698B (en) | Pyrrolopyrimidines as Protein Kinase Inhibitors | |
HRP20020547B1 (en) | Azaindoles | |
AR036106A1 (es) | Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento | |
BRPI0418082B8 (pt) | derivados de tiazol úteis como antagonistas de receptor de adenosina a2a | |
BRPI0509377A (pt) | compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1 | |
DK1020439T3 (da) | Inhibitorer af CETP-aktivitet | |
ME00590A (en) | N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | |
ATE287897T2 (de) | Analoga von nukleosiden und oligonukleotiden | |
DK0402644T3 (da) | N-(Aryloxyalkyl)-heteroarylpiperidiner og -heteroarylpiperaziner, fremgangsmåde til deres fremstilli ng samt deres anvendelse som medikamenter | |
HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
BR0307409A (pt) | Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico | |
HRP20020109B1 (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | |
BR0313297A (pt) | 6-alcóxi-pirido-pirimidinas como inibidores de p-38 map cinase | |
CO5580747A2 (es) | Derivados e intermediarios de n-adamantilmetilo como composiciones farmaceuticas y procesos para su preparacion | |
CO5540313A2 (es) | Pirrolopirimidinas como inhibidores de proteina quinasa | |
DE60105610D1 (en) | Pyrazinonderivate | |
EA200100090A2 (ru) | Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции | |
AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
HRP20030610B1 (en) | Process for the preparation of mesylates of piperazine derivatives | |
MEP12108A (en) | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them | |
RS51495B (sr) | Indolizini kao inhibitori protein kinaza | |
BRPI0414460A (pt) | compostos derivados de carboxamida do tipo de amida, composição farmacêutica e respectivo uso | |
AR011571A1 (es) | Un derivado de naftaleno, su uso, una composicion farmaceutica que lo comprende y un procedimiento para su preparacion | |
RS51518B (en) | NEW BENZOTIADIAZINE DERIVATIVES, PROCESSES OF THEIR PRODUCTION AND THE PHARMACEUTICAL MIXTURES CONTAINING THEME | |
BR0312289A (pt) | Composto, composição farmacêutica e utilização de um composto |